J. Powers

发表

Patient-reported outcomes to support medical product labeling claims: FDA perspective.

D. Patrick, L. Burke, J. Powers, 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Evidence-Based Study Design for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia

T. Fleming, J. Powers, A. Torres, 2019, The Journal of infectious diseases.

Appropriate antimicrobial prescribing: approaches that limit antibiotic resistance.

J. Powers, R. Colgan, 2001, American family physician.

Difficult-to-Treat Resistance in Gram-negative Bacteremia at 173 US Hospitals: Retrospective Cohort Analysis of Prevalence, Predictors, and Outcome of Resistance to All First-line Agents

Sameer S. Kadri, Y. Lai, J. Powers, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Standardizing measurement of chronic obstructive pulmonary disease exacerbations. Reliability and validity of a patient-reported diary.

N. Leidy, J. Powers, P. Jones, 2011, American journal of respiratory and critical care medicine.

Biomarkers and surrogate endpoints in clinical trials

T. Fleming, J. Powers, 2012, Statistics in medicine.

World Health Organization ranking of antimicrobials according to their importance in human medicine: A critical step for developing risk management strategies for the use of antimicrobials in food production animals.

F. Aarestrup, J. Powers, P. Collignon, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR).

S. Cosgrove, D. Schoenfeld, J. Powers, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Evaluation of Antihemagglutinin and Antineuraminidase Antibodies as Correlates of Protection in an Influenza A/H1N1 Virus Healthy Human Challenge Model

J. Powers, R. Davey, J. Taubenberger, 2016, mBio.

Issues in noninferiority trials: the evidence in community-acquired pneumonia.

T. Fleming, J. Powers, 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Antimicrobial drug development--the past, the present, and the future.

J. Powers, 2004, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Development of drugs for antimicrobial-resistant pathogens

J. Powers, 2003, Current opinion in infectious diseases.

Outcome Assessments in Clinical Trials of Cryptococcal Meningitis: Considerations on Use of Early Fungicidal Activity as a Potential Surrogate Endpoint for All-Cause Mortality

J. Powers, J. Montezuma-Rusca, Jairo M. Montezuma-Rusca, 2014, Current Treatment Options in Infectious Diseases.

Strategies for Clinical Management of MRSA in the Community: Summary of an Experts' Meeting Convened by the Centers for Disease Control and Prevention

J. Powers, J. Jernigan, D. Jernigan, 2006 .

Observational longitudinal study of symptom burden and time for recovery from community-acquired pneumonia reported by older adults surveyed nationwide using the CAP Burden of Illness Questionnaire

J. Powers, K. Wyrwich, Holly Yu, 2015 .

Counterpoint: alternative trial designs for antifungal drugs--time to talk.

J. Powers, 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Noninferiority trials: clinical understandings and misunderstandings.

T. Fleming, J. Powers, 2013, Clinical investigation.

Needs assessment for novel Gram-negative antibiotics in US hospitals: a retrospective cohort study

Sameer S. Kadri, Y. Lai, J. Powers, 2020, The Lancet Infectious Diseases.

Repairing the Broken Market for Antibiotic Innovation

J. Powers, M. Mcclellan, K. Outterson, 2015, Health affairs.

Analysis Populations in Anti-Infective Clinical Trials: Whom to Analyze?

J. Powers, D. Follmann, S. Evans, 2018, Statistical communications in infectious diseases.

Design, Conduct, and Analysis of Clinical Trials in Disease due to Methicillin‐Resistant Staphylococcus aureus

T. Fleming, J. Powers, T. R. Fleming, 2009, Clinical pharmacology and therapeutics.

DIAGNOSIS OF LYME DISEASE

J. Powers, J. Gill, A. Foy, 1989, The Lancet.

Evaluating Anti-infective Drugs in the Resistant Pathogen Setting: Can We Use External Controls?

J. Powers, S. Evans, 2017, Statistical communications in infectious diseases.

Ribavirin trials and hantavirus--what we should not conclude.

J. Powers, R. Johann-Liang, Kendall A. Marcus, 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Salvage therapy trials in invasive fungal disease: challenges and opportunities.

J. Powers, 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Development Of A New Patient Reported Outcome (PRO) Measure For Community-Acquired Bacterial Pneumonia (CABP)

J. Powers, S. Hoffmann, J. Crawley, 2014 .

Community-Acquired Pneumonia: Symptoms and Burden of Illness at Diagnosis among US Adults Aged 50 Years and Older

J. Powers, K. Wyrwich, Holly Yu, 2013, The Patient - Patient-Centered Outcomes Research.

Using the rate of bacterial clearance determined by real-time polymerase chain reaction to evaluate antibiotic effectiveness in Acinetobacter baumannii bacteremia.

J. Powers, B. Decker, 2013, Critical care medicine.

Fever in neurologic diseases.

J. Powers, W. Scheld, 1996, Infectious disease clinics of North America.

Progress on developing endpoints for registrational clinical trials of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections: update from the Biomarkers Consortium of the Foundation for the National Institutes of Health.

T. Fleming, J. Powers, J. Siuciak, 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Sample size and the ethics of non-inferiority trials

Charles K. Cooper, J. Powers, Daphne Lin, 2005, The Lancet.

Asking the Right Questions: Morbidity, Mortality, and Measuring What's Important in Unbiased Evaluations of Antimicrobials

J. Powers, 2012 .

Development of the EXAcerbations of Chronic Obstructive Pulmonary Disease Tool (EXACT): a patient-reported outcome (PRO) measure.

N. Leidy, J. Powers, P. Jones, 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Issues in clinical trials of prophylaxis of fungal infections.

J. Powers, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Evaluating combination therapy in community-acquired pneumonia.

Charles K. Cooper, J. Powers, 2004, Chest.

Inappropriate Empiric Antibiotic Therapy in Bloodstream Infections at U.S. Hospitals based on Discordant In vitro Susceptibilities: A Retrospective Cohort Analysis of Prevalence, Predictors and Mortality Risk

Sameer S. Kadri, Y. Lai, J. Powers, 2021 .

Antimicrobial Drug Resistance, Regulation, and Research

J. Powers, J. Metlay, R. Finch, 2006, Emerging infectious diseases.

Forum report: issues in the evaluation of diagnostic tests, use of historical controls, and merits of the current multicenter collaborative groups.

J. Powers, J. Galgiani, C. Viscoli, 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Correlation between bacteriologic eradication and clinical cure in acute otitis media.

J. Powers, R. Johann-Liang, J. Zalkikar, 2004, The Pediatric infectious disease journal.

Different Clinical Presentations of Human Rhinovirus Species Infection in Children and Adults in Mexico

J. Powers, A. Ramírez-Venegas, G. Ruiz-Palacios, 2022, Open forum infectious diseases.

Duodenal infusion of feces for recurrent Clostridium difficile.

J. Powers, T. Palmore, J. Hataye, 2013, The New England journal of medicine.

Forum report: issues in the design of trials of drugs for the treatment of invasive aspergillosis.

J. Powers, J. Galgiani, C. Viscoli, 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Forum report: issues in clinical trials of empirical antifungal therapy in treating febrile neutropenic patients.

J. Powers, J. Galgiani, C. Viscoli, 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Different epidemiological profiles in patients with Zika and dengue infection in Tapachula, Chiapas in Mexico (2016–2018): an observational, prospective cohort study

J. Powers, G. Ruiz-Palacios, J. Beigel, 2021, BMC Infectious Diseases.

Comparison of Rates of Hospitalization Between Single and Dual Virus Detection in a Mexican Cohort of Children and Adults With Influenza-Like Illness

Nora E. Bautista, J. Powers, D. Follmann, 2019, Open forum infectious diseases.

Clinical Outcome Assessments: Conceptual Foundation-Report of the ISPOR Clinical Outcomes Assessment - Emerging Good Practices for Outcomes Research Task Force.

Elizabeth Molsen, Patrick Marquis, Jeremy Hobart, 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Trends in antimicrobial drug development: implications for the future.

J. Powers, B. Spellberg, L. Miller, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Fluoroquinolone-resistant Campylobacter species and the withdrawal of fluoroquinolones from use in poultry: a public health success story.

J. Powers, T. Chiller, F. Angulo, 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Discordant minimum inhibitory concentration analysis: A new path to licensure for anti-infective drugs

J. Powers, D. Follmann, E. Brittain, 2013, Clinical trials.

Anti-infective research and development--problems, challenges, and solutions.

J. Bartlett, J. Powers, D. Pompliano, 2007, The Lancet. Infectious diseases.

Early Fungicidal Activity as a Candidate Surrogate Endpoint for All-Cause Mortality in Cryptococcal Meningitis: A Systematic Review of the Evidence

J. Powers, D. Follmann, P. Williamson, 2016, PloS one.

Considerations in clinical trials of combination antifungal therapy.

J. Powers, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Voriconazole versus liposomal amphotericin B in patients with neutropenia and persistent fever.

J. Powers, M. Goldberger, C. Dixon, 2002, The New England journal of medicine.

Development of the Flu-PRO: a patient-reported outcome (PRO) instrument to evaluate symptoms of influenza

John H. Powers, Guillermo M. Ruiz-Palacios, Christina Schofield, 2015, BMC Infectious Diseases.

Campylobacter infection and Guillain–Barré syndrome: public health concerns from a microbial food safety perspective

J. Powers, S. Foley, M. Pendrak, 2005 .

Pharmacoepidemiology of Ceftazidime-Avibactam Use: A Retrospective Cohort Analysis of 210 US Hospitals.

Sameer S. Kadri, S. Hohmann, C. Woods, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Progress in the Fight Against Multidrug-Resistant Bacteria? A Review of U.S. Food and Drug AdministrationApproved Antibiotics, 20102015

A. Kesselheim, J. Powers, K. Outterson, 2016, Annals of Internal Medicine.

Increasing the efficiency of clinical trials of antimicrobials: the scientific basis of substantial evidence of effectiveness of drugs.

J. Powers, 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Antibacterial R&D incentives

J. Powers, R. Laxminarayan, 2011, Nature Reviews Drug Discovery.

PROPHETIC: Prospective Identification of Pneumonia in Hospitalized Patients in the Intensive Care Unit.

J. Powers, M. Kollef, V. Fowler, 2020, Chest.

Adverse Effects and Antibody Titers in Response to the BNT162b2 mRNA COVID-19 Vaccine in a Prospective Study of Healthcare Workers

C. Broder, J. Powers, A. Snow, 2021, Open forum infectious diseases.

Adverse effects and antibody titers in response to the BNT162b2 mRNA COVID-19 vaccine in a prospective study of healthcare workers

C. Broder, J. Powers, A. Snow, 2021, medRxiv.

Assessment of the Perceived Acceptability of an Early Enrollment Strategy Using Advance Consent in Health Care–Associated Pneumonia

J. Powers, V. Fowler, D. Collyar, 2018, JAMA network open.

Clinician-Reported Outcome Assessments of Treatment Benefit: Report of the ISPOR Clinical Outcome Assessment Emerging Good Practices Task Force.

J. Hobart, D. Patrick, L. Burke, 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Brucella arteritis: clinical manifestations, treatment, and prognosis.

J. Powers, R. Lederman, T. Palmore, 2014, The Lancet. Infectious diseases.

Acute Epiglottitis in the Immunocompromised Host: Case Report and Review of the Literature

J. Powers, Mukil Natarajan, D. Bianchi, 2018, Open forum infectious diseases.

Grand Round Brucella arteritis : clinical manifestations , treatment , and prognosis

J. Powers, R. Lederman, T. Palmore, 2014 .

Inappropriate empirical antibiotic therapy for bloodstream infections based on discordant in-vitro susceptibilities: a retrospective cohort analysis of prevalence, predictors, and mortality risk in US hospitals.

Sameer S. Kadri, Y. Lai, J. Powers, 2020, The Lancet. Infectious diseases.

Interpreting the Results of Clinical Trials of Antimicrobial Agents

J. Powers, 2010 .

Association Between Caseload Surge and COVID-19 Survival in 558 U.S. Hospitals, March to August 2020

Lindsay M. Busch, Sameer S. Kadri, J. Powers, 2021, Annals of Internal Medicine.

Patient-Reported Outcome Assessments as Endpoints in Studies in Infectious Diseases.

J. Powers, S. Clifford, G. Talbot, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Beyond intuition: patient fever symptom experience.

N. Leidy, G. Wallen, J. Powers, 2013, Journal of pain and symptom management.

External Validation of Difficult-to-Treat Resistance Prevalence and Mortality Risk in Gram-Negative Bloodstream Infection Using Electronic Health Record Data From 140 US Hospitals.

Sameer S. Kadri, Y. Lai, J. Powers, 2019, Open forum infectious diseases.

Developing Outcomes Assessments as Endpoints for Registrational Clinical Trials of Antibacterial Drugs: 2015 Update From the Biomarkers Consortium of the Foundation for the National Institutes of Health.

J. Powers, G. Talbot, S. Hoffmann, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Development of the EXAcerbations of Chronic Obstructive Pulmonary DiseaseTool ( EXACT ) : A Patient-Reported Outcome ( PRO )

N. Leidy, J. Powers, P. Jones, 2011 .

Diagnosis and treatment of acute otitis media: evaluating the evidence.

J. Powers, 2007, Infectious disease clinics of North America.

Microbiologic Surrogate End Points in Clinical Trials of Infectious Diseases: Example of Acute Otitis Media Trials

J. Powers, 2005, Pharmacotherapy.

Complement-independent binding of microorganisms to primate erythrocytes in vitro by cross-linked monoclonal antibodies via complement receptor 1

J. Powers, W. Scheld, C. Reist, 1995, Infection and immunity.

Recommendations for improving the design, conduct, and analysis of clinical trials in hospital-acquired pneumonia and ventilator-associated pneumonia.

J. Powers, 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Empirical antifungal therapy in febrile neutropenic patients: caution about composite end points and the perils of P values.

J. Powers, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

The Fight Against Multidrug-Resistant Bacteria

A. Kesselheim, J. Powers, K. Outterson, 2017, Annals of Internal Medicine.

Using the Influenza Patient-reported Outcome (FLU-PRO) diary to evaluate symptoms of influenza viral infection in a healthy human challenge model

N. Leidy, J. Powers, J. Poon, 2018, BMC Infectious Diseases.

Reassessing the design, conduct, and analysis of clinical trials of therapy for community-acquired pneumonia.

J. Powers, 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Reliability, Validity, and Responsiveness of InFLUenza Patient-Reported Outcome (FLU-PRO©) Scores in Influenza-Positive Patients.

P. Danaher, N. Leidy, J. Powers, 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Health Affairs Repairing The Broken Market For Antibiotic Innovation

J. Powers, M. Mcclellan, K. Outterson, 2015 .

Antibiotics Approved for Marketing in Populations Specifically Excluded From Premarketing Trials, 1999-2018.

J. Powers, P. Doshi, A. Kuzucan, 2020, Mayo Clinic proceedings.

Studying new antibiotics for multidrug resistant infections: are today’s patients paying for unproved future benefits?

A. Kesselheim, J. Powers, S. Evans, 2018, British Medical Journal.

Do patient data really support the clinical and laboratory standards institute recommendation for lowering third-generation cephalosporin interpretive breakpoints?

J. Powers, P. Tamma, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Do patient data really support the CLSI recommendation for lowering third-generation cephalosporin interpretive breakpoints?

J. Powers, P. Tamma, 2013 .

A systematic approach for studying the signs and symptoms of fever in adult patients: the fever assessment tool (FAST)

N. Leidy, G. Wallen, J. Powers, 2017, Health and Quality of Life Outcomes.

Informed Consent to Study Purpose in Randomized Clinical Trials of Antibiotics, 1991 Through 2011

J. Powers, D. Morgan, Mark Jones, 2017, JAMA internal medicine.

Etiology, clinical characteristics, and risk factors associated with severe influenza-like illnesses in Mexican adults

J. Powers, A. Ramírez-Venegas, G. Ruiz-Palacios, 2023, IJID regions.

Comparison of the Impact of Zika and Dengue Virus Infection, and Other Acute Illnesses of Unidentified Origin on Cognitive Functions in a Prospective Cohort in Chiapas Mexico

J. Powers, G. Ruiz-Palacios, J. Ramos-Castañeda, 2021, Frontiers in Neurology.

Comparison of an ordinal endpoint to time-to-event, longitudinal, and binary endpoints for use in evaluating treatments for severe influenza requiring hospitalization

J. Powers, J. Neaton, D. Vock, 2019, Contemporary clinical trials communications.

Procalcitonin-Guided Antibiotic Discontinuation and Mortality in Critically Ill Adults: A Systematic Review and Meta-analysis.

J. Powers, C. Rhee, R. Danner, 2019, Chest.

Evidence at time of regulatory approval and cost of new antibiotics in 2016-19: cohort study of FDA approved drugs

A. Kesselheim, J. Powers, B. L. Brown, 2022, BMJ medicine.

Consensus on Language for Advance Informed Consent in Health Care–Associated Pneumonia Clinical Trials Using a Delphi Process

J. Powers, V. Fowler, D. Collyar, 2020, JAMA network open.

Reporting of Drug Benefit in FDA-Approved Prescription Drug Labeling

J. Powers, P. Doshi, Kyungwan Hong, 2019, Journal of General Internal Medicine.

Identifying Salient Quality of Life Domains in Patients Living with High-Risk MDS and AML

J. Powers, M. Corcoran, Sabrina Figueiredo, 2021, Blood.

Regulating Antibiotics in an Era of Resistance: The Historical Basis and Continued Need for Adequate and Well-Controlled Investigations

J. Powers, S. Podolsky, 2015, Annals of Internal Medicine.

Evaluation of Efficacy Endpoints for a Phase IIb Study of a Respiratory Syncytial Virus Vaccine in Older Adults Using Patient-Reported Outcomes With Laboratory Confirmation.

J. Powers, J. Falloon, Jing Yu, 2020, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Performance of the inFLUenza Patient-Reported Outcome (FLU-PRO) diary in patients with influenza-like illness (ILI)

P. Danaher, N. Leidy, J. Powers, 2018, PloS one.

Prospective Assessment of SARS-CoV-2 Seroconversion (PASS) study: an observational cohort study of SARS-CoV-2 infection and vaccination in healthcare workers

D. Scott, C. Broder, J. Powers, 2021, BMC Infectious Diseases.

Approval and Withdrawal of New Antibiotics and other Antiinfectives in the U.S., 1980–2009

A. Kesselheim, J. Powers, K. Outterson, 2013, Journal of Law, Medicine & Ethics.

Correlation between bacteriologic and clinical endpoints in trials of acute otitis media.

J. Powers, R. Johann-Liang, J. Zalkikar, 2003, The Pediatric infectious disease journal.

Correlation between bacteriologic eradication and clinical cure in acute otitis media.

J. Powers, R. Johann-Liang, J. Zalkikar, 2004, The Pediatric infectious disease journal.

Improving the Evidence for New Interventions in Infectious Diseases - Refocusing on Patients Instead of Pathogens and Direct Evidence for Added Patient Benefits.

J. Powers, 2020 .

Analysis of an ordinal endpoint for use in evaluating treatments for severe influenza requiring hospitalization

J. Powers, J. Neaton, S. Emery, 2017, Clinical trials.

FDA evaluation of antimicrobials: subgroup analysis.

J. Powers, D. Ross, Daphne Lin, 2005, Chest.

Linezolid and vancomycin for methicillin-resistant Staphylococcus aureus nosocomial pneumonia: the subtleties of subgroup analyses.

J. Powers, Daphne Lin, D. B. Ross, 2004, Chest.

Clinician-reported lesion measurements in skin infection trials: Definitions, reliability, and association with patient-reported pain.

J. Powers, P. Prokocimer, C. D. De Anda, 2016, Contemporary clinical trials.

Quality of life of HIV-negative, previously healthy individuals following cryptococcal meningoencephalitis

J. Powers, P. Williamson, Jing Wang, 2021, Scientific Reports.

Understanding the life experience of Barth syndrome from the perspective of adults: a qualitative one-on-one interview study

A. Shields, J. Powers, P. Barth, 2019, Orphanet Journal of Rare Diseases.

The United States Food and Drug Administration and noninferiority margins in clinical trials of antimicrobial agents.

J. Powers, E. Brittain, M. Goldberger, 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Diagnosis of lyme disease.

J. Powers, J. Gill, A. Foy, 2005, American family physician.

Risk perception and inappropriate antimicrobial use: yes, it can hurt.

J. Powers, John H Powers, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Levofloxacin and macrolides for treatment of Legionnaires disease: multiple comparisons give few answers.

J. Powers, J. Zalkikar, C. Kraus, 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

A Comparative Assessment of Approvals and Discontinuations of Systemic Antibiotics and Other Therapeutic Areas

J. Powers, E. Seoane-Vazquez, R. Rodriguez-Monguio, 2023, Healthcare.

Candidemia in the ICU: Does Initial Antifungal Matter?

J. Powers, J. Bennett, 2018, Critical care medicine.

Analysis Populations in Anti-Infective Clinical Trials: Whom to Analyze?

J. Powers, D. Follmann, S. Evans, 2018, Statistical communications in infectious diseases.

Noninferiority and equivalence trials: deciphering ‘similarity’ of medical interventions

J. Powers, 2008, Statistics in medicine.

The Wrong Cure: Financial Incentives for Unimpressive New Antibiotics.

A. Kesselheim, J. Powers, M. Sinha, 2020, The Journal of infectious diseases.

Comparison of clinical characteristics of Zika and dengue symptomatic infections and other acute illnesses of unidentified origin in Mexico

J. Powers, G. Ruiz-Palacios, J. Beigel, 2021, PLoS neglected tropical diseases.

Clinician-reported lesion measurements in skin infection trials: Definitions, reliability, and association with patient-reported pain.

J. Powers, P. Prokocimer, Anita Das, 2016, Contemporary clinical trials.

Analysis of an ordinal endpoint for use in evaluating treatments for severe influenza requiring hospitalization

J. Powers, J. Neaton, S. Emery, 2017, Clinical trials.

Sample size and the ethics of non-inferiority trials

Charles K. Cooper, J. Powers, Daphne Lin, 2005, The Lancet.

Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR).

S. Cosgrove, D. Schoenfeld, J. Powers, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

J. Powers, K. Wyrwich, R. Sato, 2022 .

Repairing the Broken Market for Antibiotic Innovation

J. Powers, M. Mcclellan, Gregory W. Daniel, 2015, Health affairs.